US · Healthcare · Biotechnology
EPS came in at -1.06 against a street estimate of -0.58 — a miss of 82.8%.
Analysts rate Boundless Bio, Inc. Common Stock a hold (0 buy, 1 hold, 0 sell out of 1) with an average price target of $4.00.
| Fund | Stake |
|---|---|
| ARCH VENTURE CORP | 11.84% |
| FMR Inc | 11.35% |
| TANG CAPITAL MANAGEMENT LLC | 11.25% |
| ADAR1 Capital Management LLC | 8.65% |
| Cormorant Asset Management, LLC | 4.40% |
| Vanguard Capital Management, LLC | 2.70% |
| Wellington Management Company LLP | 2.45% |
| Millennium Management LLC | 2.10% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Boundless Bio, Inc. Common Stock — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.